Slide 1

Clinical Knowledge Summaries CKS Deep venous thrombosis (DVT) Diagnosis and management in primary care. Educational slides based on the CKS topic DVT (April 2013) and NICE guidance (2012a): Venous thromboembolic disease: the management of venous thromboembolic diseases and the role of thrombophilia testing.

Slide 2

Key learning points and objectives To be able to: oAssess the likelihood of a DVT being present, using the two-level DVT Wells score. oRecognise people who are considered to be at high risk of DVT and need same day assessment. oDescribe when it is appropriate to give a parenteral anticoagulant and which one should be offered. oOutline what management and follow up is required after discharge from hospital. Based on the CKS topic DVT (April 2013) and NICE guidance (2012a); Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing.

Slide 3

DVT background information DVT is the formation of a blood clot in a deep vein. Usually in the legs; partially or completely obstructs blood flow. Annual incidence is about 1 in 1000 people. The most serious complication is pulmonary embolism. Only about a third of people with a clinical suspicion of DVT have the condition. Based on the CKS topic DVT (April 2013) and NICE guidance (2012a); Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing.

Slide 4

Risk factors for DVT Risk factors include: oPrevious venous thromboembolism. oCancer (known or undiagnosed). oIncreasing age. oBeing overweight or obese. oMale sex. oHeart failure. oAcquired or familial thrombophilia. oChronic low-grade injury to the vascular wall (for example vasculitis, hypoxia from venous stasis, or chemotherapy). Based on the CKS topic DVT (April 2013) and NICE guidance (2012a); Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing.

Slide 5

Temporary risk factors Risk factors that temporarily raise the likelihood of DVT: oImmobility, significant trauma, or direct trauma to a vein. oHormone treatment (for example oestrogen- containing contraception or hormone replacement therapy). oPregnancy and the postpartum period. oDehydration. Based on the CKS topic DVT (April 2013) and NICE guidance (2012a); Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing.

Slide 6

What else might it be? Physical trauma: oCalf muscle tear or strain. oHaematoma (collection of blood) in the muscle. oSprain or rupture of the Achilles tendon. oFracture. Based on the CKS topic DVT (April 2013) and NICE guidance (2012a); Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing.

Slide 7

What else might it be? Cardiovascular disorders: oSuperficial thrombophlebitis. oPost-thrombotic syndrome. oVenous obstruction or insufficiency, or external compression of major veins (for example by a fetus during pregnancy, or cancer). oArteriovenous fistula and congenital vascular abnormalities. oAcute limb ischaemia. oVasculitis. oHeart failure. Based on the CKS topic DVT (April 2013) and NICE guidance (2012a); Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing.

Slide 8

What else might it be? Other conditions including: oRuptured Baker's cyst. oCellulitis (commonly mistaken as DVT). oDependent (stasis) oedema. oLymphatic obstruction. oSeptic arthritis. oCirrhosis. oNephrotic syndrome. oCompartment syndrome. Based on the CKS topic DVT (April 2013) and NICE guidance (2012a); Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing.

Slide 9

When to suspect a DVT Suspect a DVT if the person has: o Signs or symptoms of a DVT: Pain and swelling in one leg, although both legs may be affected. Tenderness, changes to skin colour and temperature, and vein distension. o A risk factor for DVT (e.g. previous VTE and immobility). To exclude an alternative cause: o Carry out a physical examination. o Review the person's general medical history. Based on the CKS topic DVT (April 2013) and NICE guidance (2012a); Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing.

Slide 10

Managing a suspected DVT Refer immediately if pregnant or given birth within the past 6 weeks. o Requires same-day assessment and management as it is n ot possible to accurately assess the risk of DVT in primary care. For everyone else, use the two-level DVT Wells score to assess likelihood of DVT and inform further management. Based on the CKS topic DVT (April 2013) and NICE guidance (2012a); Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing.

Slide 11

Two-level DVT Wells score Validated, simple scoring system that takes into account previous DVT. o DVT is likely if the score is two points or more. o DVT is unlikely if the score is one point or less. Based on the CKS topic DVT (April 2013) and NICE guidance (2012a); Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing.

Slide 12

Using the two-level DVT Wells score Score one point for each of the following: oActive cancer (treatment ongoing, within the last 6 months, or palliative). oParalysis, paresis, or recent plaster immobilization of the legs. oRecently bedridden for 3 days or more, or major surgery within the last 12 weeks requiring general or local anaesthetics. oLocalized tenderness along the distribution of the deep venous system (such as the back of the calf). oEntire leg is swollen. oCalf swelling by more than 3 cm compared with the asymptomatic leg (measured 10 cm below the tibial tuberosity). oPitting oedema (greater than on the asymptomatic leg). oCollateral superficial veins (non-varicose). oPreviously documented DVT. Subtract two points if an alternative cause is considered more likely than DVT. Based on the CKS topic DVT (April 2013) and NICE guidance (2012a); Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing.

Slide 13

Other methods of assessment Do not use: oIndividual symptoms and signs on their own. On their own they are poor predictors of the presence or absence of DVT. oA positive Homans' sign (pain in the calf or popliteal region on passive, abrupt, forceful dorsiflexion of the ankle with the knee in a flexed position): Is insensitive and nonspecific. Can be painful, and there is a theoretical possibility of dislodging a thrombus. Based on the CKS topic DVT (April 2013) and NICE guidance (2012a); Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing.

Slide 14

If DVT likely (>2 points) Refer for a proximal leg vein ultrasound scan to be carried out within 4 hours. If a proximal leg vein ultrasound scan cannot be carried out within 4 hours of being requested: oTake a blood sample for D-dimer testing. oGive an interim 24-hour dose of a parenteral anticoagulant (weight required to calculate the dose). Ensure a proximal leg vein ultrasound scan is carried out within 24 hours of being requested. Based on the CKS topic DVT (April 2013) and NICE guidance (2012a); Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing.

Slide 15

Which parenteral anticoagulant? Offer a choice of low molecular weight heparin (LMWH) or fondaparinux. oLicensed LMWHs for DVT treatment include dalteparin, enoxaparin, and tinzaparin. oFondaparinux is a synthetic pentasaccharide that inhibits activated factor X. Choice of parenteral anticoagulant depends on: oComorbidities, contraindications, and cost. Local policy may also influence choice. Based on the CKS topic DVT (April 2013) and NICE guidance (2012a); Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing.

Slide 16

If DVT unlikely (< 1point) Offer D-dimer testing. If negative D-dimer test - consider an alternative diagnosis to explain symptoms. If positive D-dimer test - refer for a proximal leg vein ultrasound scan to be carried out within 4 hours. If a proximal leg vein ultrasound scan cannot be carried out within 4 hours of being requested: oGive an interim 24-hour dose of a parenteral anticoagulant (weight required to calculate the dose). Ensure a proximal leg vein ultrasound scan is carried out within 24 hours of being requested. Based on the CKS topic DVT (April 2013) and NICE guidance (2012a); Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing.

Slide 17

Treatment in secondary care Once a DVT has been confirmed in secondary care, most people will be initiated on long term treatment (3 months or longer) with either: oAn oral anticoagulant (warfarin or rivaroxaban), or oA LMWH. LMWH are usually indicated if oral anticoagulants are: oContraindicated, for example pregnancy, or oLess preferred, for example cancer. Based on the CKS topic DVT (April 2013) and NICE guidance (2012a); Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing.

Slide 18

Follow up for DVT At follow up ensure: o That people with an unprovoked DVT are: o Investigated for the possibility of an undiagnosed cancer, and o Have been offered thrombophilia testing, as appropriate. o Adequate regular monitoring for warfarin or rivaroxaban. o Monitoring requirements for warfarin and rivaroxaban differ. o That below-knee compression stockings have been prescribed. Based on the CKS topic DVT (April 2013) and NICE guidance (2012a); Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing.

Slide 19

Monitoring warfarin For people taking warfarin monitor the international normalized ratio (INR) and adjust the dose as required. The target INR for people with a DVT is between 2 and 3 (ideally 2.5). Usually monitor INR: oInitially - daily, or every other day, until within therapeutic range, then oTwice weekly for 12 weeks, then oWeekly until at least two INR measurements are within range, thereafter oDepends on the stability of the INR but usually longer intervals (e.g. up to every 12 weeks). Based on the CKS topic Anticoagulation 0ral (May 2013)

Slide 20

Monitoring rivaroxaban No need to monitor the INR, however oRegular follow up and monitoring is still required. Follow up every 3 months to assess for: oConcordance and adverse effects (e.g. bleeding). Repeat renal and liver function tests as well as the full blood count at least once a year. Repeat renal function tests: oEvery six months if the person has a creatinine clearance (CrCl) of 3060 mL/min. oEvery three months if the person has a CrCl of 15 30 mL/min. If renal function has declined, review treatment. oRivaroxaban may need to be stopped or the dose lowered. Based on the CKS topic Anticoagulation 0ral (May 2013)

Slide 21

Compression stockings Before prescribing: o Exclude arterial insufficiency. o Check the condition of the skin. o Fragile skin may be damaged when putting on or taking off stockings. o Consider if the person in likely to be able to manage the stockings. Arthritis - may be difficult to get stockings on and off. May need application aid/help from community nurse. Based on the CKS topic Compression stockings (September 2012).

Slide 22

Compression stockings Class 3 stockings are preferred but may be poorly tolerated. Class 2 can be used as an alternative. Usually worn for 2 years (unless there are contraindications). Prescribe a spare pair (one to wear and one in the wash). Renew every 36 months. Re-measure leg each time to ensure correct fit. Based on the CKS topic DVT (April 2013) and NICE guidance (2012a); Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing.

Slide 23

Advice to patients Walk regularly after discharge from hospital. Elevate the affected leg when sitting. Refrain from extended travel, or travel by aeroplane, for at least 2 weeks after starting anticoagulant treatment. Based on the CKS topic DVT (April 2013) and NICE guidance (2012a); Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing.

Slide 24

Summary Only a third of people with a clinical suspicion of DVT have the condition. If DVT suspected and the person is pregnant or has given birth within the past 6 weeks refer immediately. For everyone else use the two-level DVT Wells score to assess likelihood of DVT. o DVT is likely if the score is two points or more. o DVT is unlikely if the score is one point or less. If DVT likely, refer for a proximal leg vein ultrasound scan (carried out within 4 hours). oGive a parenteral anticoagulant and do a d-dimer test if ultrasound cannot be carried out with in 4 hours. If DVT unlikely, offer D-dimer test, if positive - refer for proximal leg vein ultrasound scan (carried out within 4 hours). oGive a parenteral anticoagulant if ultrasound cannot be carried out with in 4 hours.